# Acurx Pharmaceuticals Inc. (ACXP)

Source: https://www.quantisnow.com/company/ACXP
Generated: 2026-11-07T02:27:46.034Z

- Ticker: ACXP
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- SEC CIK: 0001736243
- Website: acurxpharma.com

## About

Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.

## Latest ACXP news and filings

- 2026-10-29 21:20 UTC [SEC Form 8-K] [SEC Form 8-K filed by Acurx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-acurx-pharmaceuticals-inc-6764112)
- 2026-10-26 12:01 UTC [Earnings Date] [Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update](https://www.quantisnow.com/insight/acurx-pharmaceuticals-to-discuss-third-quarter-2026-financial-results-on-6757074)
- 2026-10-21 12:01 UTC [Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect](https://www.quantisnow.com/insight/acurx-announces-publication-in-asm-confirming-data-on-its-dna-6753006)
- 2026-10-16 20:30 UTC [SEC Form 8-K] [SEC Form 8-K filed by Acurx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-acurx-pharmaceuticals-inc-6749297)
- 2026-09-29 12:01 UTC [Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection](https://www.quantisnow.com/insight/acurx-pharmaceuticals-announces-first-patient-enrolled-in-pathfinder-clinical-trial-6728476)
- 2026-09-18 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Acurx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-acurx-pharmaceuticals-inc-6719940)
- 2026-09-17 20:52 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Acurx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-acurx-pharmaceuticals-inc-6719490)
- 2026-09-14 12:01 UTC [Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures](https://www.quantisnow.com/insight/acurx-announces-presentation-of-a-scientific-poster-at-the-premier-6713818)
- 2026-09-08 20:27 UTC [SEC Form S-1] [SEC Form S-1 filed by Acurx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-acurx-pharmaceuticals-inc-6708454)
- 2026-09-01 20:16 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Acurx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-acurx-pharmaceuticals-inc-6701479)
- 2026-09-01 20:15 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Acurx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-acurx-pharmaceuticals-inc-6701463)
- 2026-08-17 12:01 UTC [Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat](https://www.quantisnow.com/insight/acurx-pharmaceuticals-receives-fda-conditional-acceptance-and-uspto-trademark-allowance-6684316)
- 2026-08-14 11:01 UTC [Public Offering] [Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update](https://www.quantisnow.com/insight/acurx-pharmaceuticals-inc-reports-second-quarter-2026-results-and-provides-6681780)
- 2026-08-13 20:07 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Acurx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-acurx-pharmaceuticals-inc-6680390)
- 2026-08-12 12:01 UTC [Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics](https://www.quantisnow.com/insight/japan-and-mexico-patent-offices-both-grant-acurx-pharmaceuticals-new-6677095)
- 2026-08-10 12:01 UTC [Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics](https://www.quantisnow.com/insight/acurx-announces-scientific-partnership-with-leiden-university-medical-center-to-6672828)
- 2026-08-03 12:00 UTC [FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection](https://www.quantisnow.com/insight/fda-provides-further-regulatory-guidance-to-acurx-pharmaceuticals-for-the-6658784)
- 2026-07-14 12:00 UTC [Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection](https://www.quantisnow.com/insight/acurx-pharmaceuticals-announces-scientific-poster-presentation-of-ibezapolstats-microbiome-preservation-6636117)
- 2026-07-08 12:00 UTC [Earnings Date] [Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update](https://www.quantisnow.com/insight/acurx-pharmaceuticals-to-discuss-second-quarter-2026-financial-results-on-6630935)
- 2026-06-16 12:00 UTC [Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference](https://www.quantisnow.com/insight/acurx-pharmaceuticals-announces-presentation-of-results-from-leiden-university-medical-6603947)
- 2026-05-12 19:05 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Acurx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-acurx-pharmaceuticals-inc-6547642)
- 2026-05-12 19:04 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Acurx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-acurx-pharmaceuticals-inc-6547639)
- 2026-05-12 11:01 UTC [Public Offering] [Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update](https://www.quantisnow.com/insight/acurx-pharmaceuticals-inc-reports-first-quarter-2026-results-and-provides-6546576)
- 2026-05-12 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Acurx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-acurx-pharmaceuticals-inc-6546387)
- 2026-05-12 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Acurx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-acurx-pharmaceuticals-inc-6546376)
- 2026-05-11 20:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Acurx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-acurx-pharmaceuticals-inc-6544834)
- 2026-05-04 20:09 UTC [SEC Form S-1] [SEC Form S-1 filed by Acurx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-acurx-pharmaceuticals-inc-6529049)
- 2026-05-04 20:08 UTC [SEC Form S-1] [SEC Form S-1 filed by Acurx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-acurx-pharmaceuticals-inc-6529015)
- 2026-05-04 12:00 UTC [Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026](https://www.quantisnow.com/insight/acurx-announces-scientific-poster-presentation-of-its-dna-pol-iiic-6528073)
- 2026-04-29 20:17 UTC [SEC Form D] [SEC Form D filed by Acurx Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-acurx-pharmaceuticals-inc-6521488)
- 2026-04-29 12:00 UTC [Conference Announcement] [Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase](https://www.quantisnow.com/insight/acurx-pharmaceuticals-to-present-at-the-alliance-global-partners-agp-6520207)
- 2026-04-22 20:21 UTC [SEC Form 4] [SEC Form 4 filed by Sailer Carl](https://www.quantisnow.com/insight/sec-form-4-filed-by-sailer-carl-6510559)
- 2026-04-22 20:20 UTC [SEC Form 4] [SEC Form 4 filed by Dean Jack H](https://www.quantisnow.com/insight/sec-form-4-filed-by-dean-jack-h-6510555)
- 2026-04-22 20:20 UTC [SEC Form 4] [SEC Form 4 filed by Donohue James J.](https://www.quantisnow.com/insight/sec-form-4-filed-by-donohue-james-j-6510550)
- 2026-04-22 20:19 UTC [SEC Form 4] [SEC Form 4 filed by Harrison Thomas L](https://www.quantisnow.com/insight/sec-form-4-filed-by-harrison-thomas-l-6510541)
- 2026-04-22 20:19 UTC [SEC Form 4] [SEC Form 4 filed by Scodari Joseph C](https://www.quantisnow.com/insight/sec-form-4-filed-by-scodari-joseph-c-6510540)
- 2026-04-22 20:18 UTC [SEC Form 4] [SEC Form 4 filed by Deluccia Robert J](https://www.quantisnow.com/insight/sec-form-4-filed-by-deluccia-robert-j-6510531)
- 2026-04-22 20:17 UTC [SEC Form 4] [SEC Form 4 filed by Luci David P](https://www.quantisnow.com/insight/sec-form-4-filed-by-luci-david-p-6510527)
- 2026-04-22 20:16 UTC [SEC Form 4] [SEC Form 4 filed by Shawah Robert G.](https://www.quantisnow.com/insight/sec-form-4-filed-by-shawah-robert-g-6510517)
- 2026-04-20 12:00 UTC [Earnings Date] [Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update](https://www.quantisnow.com/insight/acurx-pharmaceuticals-to-discuss-first-quarter-2026-financial-results-on-6506023)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ACXP
- Earnings history: https://www.quantisnow.com/earnings/ACXP
- Dividend history: https://www.quantisnow.com/dividends/ACXP
- Insider transactions: https://www.quantisnow.com/insiders/ACXP
- Options chain: https://www.quantisnow.com/options/ACXP
- SEC 8-K filings only: https://www.quantisnow.com/company/ACXP/8-k
- RSS and alerts for ACXP: https://www.quantisnow.com/docs/rss-feeds.md